Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
394.3 USD | +0.21% | -0.39% | -2.92% |
Apr. 18 | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.92% | 102B | |
+1.81% | 96.07B | |
-1.80% | 21.66B | |
-17.91% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-27.92% | 13.79B | |
0.00% | 13.33B | |
+19.05% | 10.94B | |
-23.38% | 8.57B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Transcript : Vertex Pharmaceuticals Incorporated Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 08